Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a …
Read MoreThe U.S. Food and Drug Administration recently announced that it has awarded six new clinical trial research grants to principal investigators from academia and industry totaling over $16 million over …
Read MoreThe U.S. Food and Drug Administration granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the …
Read MoreWASHINGTON, D.C. — The U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a …
Read More